Joseph Zarge, MD
Vascular Surgery · Atlanta, GANPI 1528006525
Payments from drug & device makers
Across 18 payments — averaging $509.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Silk Road Medical, Inc.$4K
- Artivion, Inc.$3K
- W. L. Gore & Associates, Inc.$1K
- KCI USA, Inc.$850
- Shockwave Medical, Inc$125
- Boston Scientific$23
- plus $5 from 1 others
What the payments were for
- Consulting fees$85017%
- Speaking & faculty fees$2,50049%
- Food & beverage$1,74134%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Silk Road Medical, Inc. | 5 | $4,416 |
| Artivion, Inc. | 1 | $2,500 |
| W. L. Gore & Associates, Inc. | 8 | $1,252 |
| KCI USA, Inc. | 1 | $850 |
| Shockwave Medical, Inc | 1 | $125 |
| Boston Scientific | 1 | $23 |
| Intuitive Surgical | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cardiac non-SynerGraft$2,500
- PREVENA$850
- GORE VIABAHN VBX Balloon Expandable Endo$506
- ENROUTE Transcarotid Neuroprotection System$336
- ENHANCE Transcarotid Peripheral Access Kit$336
- VIABAHN VBX Balloon Expandable Endoprosthesis$298
- ENROUTE Transcarotid Stent System$195
- ENROUTE 0.014 Guidewire$195
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$172
- GORE EXCLUDER AAA Endoprosthesis$146
- ENROUTE .014 Guidewire$141
- ENROUTE Transcarotid Stent$141
- C3 Delivery System$129
- Vascular Lithotripsy$125
How this compares
$9,171 in reported general payments places this provider in the 60th percentile of 176 vascular surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 104 | $75,753 |
| XareltoRivaroxaban | 54 | $47,030 |
| ClopidogrelClopidogrel Bisulfate | 216 | $2,072 |
| Cilostazol | 109 | $1,920 |
| Gabapentin | 44 | $571 |
| Atorvastatin Calcium | 37 | $277 |
| Rosuvastatin Calcium | 15 | $237 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 38 | $203 |
| Oxycodone Hcl | 13 | $137 |
| Tramadol Hcl | 19 | $32 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Atlanta
- Siddharth PatelAtlanta$381K
- Yazan DuwayriAtlanta$284K
- Charles RossAtlanta$178K
- Andrew UnzeitigAtlanta$96K
- Jaime Benarroch GampelAtlanta$84K
- Walaya Methodius-RayfordAtlanta$79K
- Christopher RamosAtlanta$48K
- Peter H DoublerAtlanta$47K
- Jorge CorsoAtlanta$41K
- Anumeha WhisenhuntAtlanta$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.